-
11.发明申请TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS 有权三唑盐作为PAR1抑制剂，其生产和用作药物公开(公告)号：US20110034452A1
公开(公告)日：2011-02-10
申请号：US12851219
申请日：2010-08-05
IPC分类号： A61K31/536 , C07D487/04 , C07D471/04 , A61K31/5025 , A61K31/5377 , A61K31/437 , A61P7/02 , A61P29/00 , A61P9/10 , A61P9/00 , A61P11/00 , A61P9/06 , A61P3/10 , A61P35/00 , A61P35/04
CPC分类号： C07D487/04 , C07D471/04
摘要： The invention relates to novel compounds of formula I where X, A−, Q1, Q2 Q3, R2, R3, R4, R5, R6, R7, R8 and R9 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
摘要翻译： 本发明涉及新的式I化合物，其中X，A-，Q1，Q2 Q3，R2，R3，R4，R5，R6，R7，R8和R9各自如下所定义。 式I的化合物具有抗血栓形成活性并特别抑制蛋白酶活化的受体1（PAR1）。 本发明还涉及制备式I化合物及其作为药物的用途的方法。
-
12.发明申请TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS 有权作为PAR1抑制剂的三唑并吡嗪，其生产和用作药物公开(公告)号：US20110034451A1
公开(公告)日：2011-02-10
申请号：US12851189
申请日：2010-08-05
申请人： Uwe HEINELT , Volkmar WEHNER , Matthias HERRMANN , Karl SCHOENAFINGER , Henning STEINHAGEN , Bodo SCHEIPER
发明人： Uwe HEINELT , Volkmar WEHNER , Matthias HERRMANN , Karl SCHOENAFINGER , Henning STEINHAGEN , Bodo SCHEIPER
IPC分类号： A61K31/538 , C07D487/04 , A61K31/5025 , A61K31/5377 , A61P7/02 , A61P9/10 , A61P9/00 , A61P11/00 , A61P9/06 , A61P29/00 , A61P3/10 , A61P35/00 , A61P35/04
CPC分类号： C07D487/04 , A61K31/5025
摘要： The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
摘要翻译： 本发明涉及新的式I化合物，其中R1，R2，R3，R4，R5，R6，R7，R8，Q1，Q2和Q3各自如下所定义。 式I的化合物具有抗血栓形成活性并特别抑制蛋白酶活化的受体1（PAR1）。 本发明还涉及制备式I化合物及其作为药物的用途的方法。
-
13.发明申请CYCLIC (AZA)INDOLIZINECARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS 有权CYCLIC（AZA）吲哚类胆固醇，其制备及其作为药物的用途公开(公告)号：US20120232081A1
公开(公告)日：2012-09-13
申请号：US13353889
申请日：2012-01-19
申请人： Henning STEINHAGEN , Bodo SCHEIPER , Hans MATTER , Gary MCCORT , Guillaume BEGIS , Pascale GOBERVILLE , Berangere THIERS
发明人： Henning STEINHAGEN , Bodo SCHEIPER , Hans MATTER , Gary MCCORT , Guillaume BEGIS , Pascale GOBERVILLE , Berangere THIERS
IPC分类号： A61K31/496 , A61P9/04 , A61P9/00 , A61K31/5025 , A61P27/06 , A61P9/10 , C07D471/04 , C07D487/04 , A61P9/12 , A61P13/12
CPC分类号： C07D471/04 , C07D487/04
摘要： The present invention relates to cyclic indolizinecarboxamides and azaindolizinecarboxamides of the formulae Ia and Ib, wherein R, Ra, R10, R20, R30, R40, Y, n, p and q have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they inhibit the enzyme renin and modulate the activity of the renin-angiotensin system, and are useful for the treatment of diseases such as hypertension, for example. The invention furthermore relates to processes for the preparation of the compounds of the formulae Ia and Ib, their use and pharmaceutical compositions comprising them.
摘要翻译： 本发明涉及式Ⅰa和Ⅰb的环吲哚嗪甲酰胺和氮杂吲哚烷甲酰胺，其中R，Ra，R10，R20，R30，R40，Y，n，p和q具有权利要求中所示的含义，它们是有价值的药物活性化合物 。 具体地说，它们抑制酶肾素并调节肾素 - 血管紧张素系统的活性，并且可用于治疗例如高血压等疾病。 本发明还涉及制备式Ia和Ib化合物的方法，其用途和包含它们的药物组合物。
-
14.发明申请IMIDAZOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS 有权咪达唑啶作为PAR1抑制剂，其生产和用作药物公开(公告)号：US20110034456A1
公开(公告)日：2011-02-10
申请号：US12851198
申请日：2010-08-05
IPC分类号： A61K31/5377 , C07D487/04 , A61K31/5025 , A61P9/10 , A61P9/00 , A61P7/02 , A61P29/00 , A61P3/10 , A61P35/00 , A61P35/04 , A61P19/02 , A61P11/00 , A61P3/00 , A61P9/06
CPC分类号： C07D487/04
摘要： The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, R9, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
摘要翻译： 本发明涉及新的式I化合物，其中R1，R2，R3，R4，R5，R6，R7，R8，R9，Q1，Q2和Q3各自如下所定义。 式I的化合物具有抗血栓形成活性并特别抑制蛋白酶活化的受体1（PAR1）。 本发明还涉及制备式I化合物及其作为药物的用途的方法。
-
-
-
搜索结果
14 条记录 (耗时 0.028 秒)
